BioNTech Charts New Course: Founders to Exit by 2026 as Restructuring and Cancer Data Collide

BioNTech is navigating one of the most consequential transitions in its history. The German biotech, which shot to global prominence on the back of its Covid-19 vaccine, is simultaneously restructuring its workforce, shuttering production sites, and preparing for a leadership change that will see founders Ugur Sahin and Özlem Türeci step back from operational roles at the end of next year. The strategic overhaul comes as the company’s oncology pipeline – long the core thesis for investors – begins to produce its first late-stage clinical signals.

The scale of the corporate reset is hard to overstate. Around 1,860 employees, or 20% of the global headcount, will be cut. Five sites are earmarked for closure by the end of 2027, four of them in Germany – Idar-Oberstein, Marburg, Tübingen – and one in Singapore. The Marburg site alone houses eight production suites capable of churning out mRNA for up to three billion vaccine doses annually. BioNTech expects the cost savings to reach €500 million per year by 2029, with the funds redirected into its oncology push. Beyond that, the company is exploring sales of affected production facilities, with decisions expected by the end of the third quarter.

The financial backdrop to this restructuring is a picture of post-pandemic normalisation. First-quarter 2026 revenue tumbled 33% to €118.1 million, and the net loss widened to €531.9 million, or €2.10 per diluted share. Yet the balance sheet remains a fortress: BioNTech held about €16.8 billion in cash, cash equivalents and securities at the end of March, and has launched a share buyback programme of up to $1 billion over twelve months. The company is still guiding for full-year 2026 revenue of €2.0?billion to €2.3?billion, with a steep R&D spend of €2.2?billion to €2.5?billion.

Should investors sell immediately? Or is it worth buying BioNTech?

That investment is flowing directly into a pipeline that now features more than 25 Phase 2 and Phase 3 studies, 13 of them registrational. The most immediate data came from the ASCO conference in Chicago, where BioNTech, together with Bristol Myers Squibb, presented Phase II results for pumitamig, a bispecific antibody targeting PD-L1 and VEGF. In the ROSETTA Lung-02 trial, the drug delivered a confirmed objective response rate of 57.1% in patients with non-squamous non-small cell lung cancer, and 68.4% in squamous disease. At a lower dose, response rates climbed to 63.6% and 72.7%, respectively. The caveat: treatment-related grade 3 or higher adverse events occurred in 44% of patients, underscoring that tolerability will be a key variable in later-stage development.

Analyst reactions to the pipeline progress have been mixed, reflecting the uncertainty that still surrounds the transition. UBS upgraded BioNTech from Neutral to Buy and lifted its price target to $135 from $117, citing growing confidence in the late-stage oncology portfolio. Bernstein, by contrast, initiated coverage with a Market Perform rating and a $96 target, arguing that proof of commercial viability remains some way off. The stock traded at $97.02 on June 1, down about 7% year-to-date and roughly 25% lower than twelve months ago.

Beyond pumitamig, the company has other late-stage assets that could shift the narrative. Gotistobart, a CTLA-4 antibody, is being evaluated in the pivotal PRESERVE-003 study, with interim data expected later this year. BNT113, a mRNA-based immunotherapy, is also approaching a Phase 3 readout. In total, six more late-stage data sets are scheduled before the end of 2026, including immunomodulators, antibody-drug conjugates and mRNA cancer vaccines.

The leadership dimension adds another layer of uncertainty. Sahin and Türeci, who steered BioNTech from a small Mainz startup to a pandemic-era giant, plan to exit their operational roles by end-2026 to launch a new venture focused on mRNA therapies. The incoming management team inherits a clear but demanding goal: secure regulatory approvals in ten cancer indications by 2030. Whether the pipeline can deliver against that timeline – and whether the restructuring can be executed without sacrificing momentum – will determine whether BioNTech’s second act lives up to the promise of its first.

Ad

BioNTech Stock: New Analysis - 3 June

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69475899 |